COPD - Nationale VersorgungsLeitlinien

68. Lehtonen J, Sutinen S, Ikaheimo M, Paakko P. Electrocardiographic criteria for the diagnosis of right
ventricular hypertrophy verified at autopsy. Chest 1988;93(4):839-42.
69. Niedermeier J, Barner M, Borst M. Empfehlungen zur Anwendung der Echokardiographie in der
pneumologischen Diagnostik. Deutsche Gesellschaft für Pneumologie. Pneumologie 1998;52:232-7.
70. Wolkove N, Dajczman E, Colacone A, Kreisman H. The relationship between pulmonary function and
dyspnea in obstructive lung disease. Chest 1989;96(6):1247-51.
71. Connolly MJ, Crowley JJ, Charan NB, Nielson CP, Vestal RE. Reduced subjective awareness of
bronchoconstriction provoked by methacholine in elderly asthmatic and normal subjects as
measured on a simple awareness scale. Thorax 1992;47(6):410-3.
72. van Schayck CP, Dompeling E, van Herwaarden CL, Folgering H, Verbeek AL, van der Hoogen HJ,
van Weel C. Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on
demand? A randomised controlled study. BMJ 1991;303(6815):1426-31.
73. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary
disease. N Engl J Med 2000;343(26):1902-9.
74. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double
blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic
obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320(7245):1297-303.
75. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide
in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet
1999;353(9167):1819-23.
76. Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, Ohlsson SV. Long-term
treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who
continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.
N Engl J Med 1999;340(25):1948-53.
77. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA, Jr., Enright PL,
Kanner RE, O'Hara P. Effects of smoking intervention and the use of an inhaled anticholinergic
bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994;272(19):1497-
505.
78. Voshaar T, App EM, Berdel D, Buhl R, Fischer J, Gessler T, Haidl P, Heyder J, Köhler D, Kohlhaufl
M, Lehr CM, Lindemann H, Matthys H, Meyer T, Olschewski H, Paul KD, Rabe K, Raschke F,
Scheuch G, Schmehl T, Schultze-Werninghaus G, Ukena D, Worth H. Empfehlungen für die
Auswahl von Inhalationssystemen zur Medikamentenverabreichung. Pneumologie 2001;55(12):579-
86.
79. Rote Liste Service GmbH. Rote Liste. Ausgabe 2005. Aulendorf: Edition Cantor Verl.; 2004.
Available from: http://www.rote-liste.de
80. Nisar M, Earis JE, Pearson MG, Calverley PM. Acute bronchodilator trials in chronic obstructive
pulmonary disease. Am Rev Respir Dis 1992;146(3):555-9.
81. Boyd G, Morice AH, Pounsford JC, Siebert M, Peslis N, Crawford C. An evaluation of salmeterol in
the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997;10(4):815-21.
82. Grove A, Lipworth BJ, Reid P, Smith RP, Ramage L, Ingram CG, Jenkins RJ, Winter JH, Dhillon DP.
Effects of regular salmeterol on lung function and exercise capacity in patients with chronic
obstructive airways disease. Thorax 1996;51(7):689-93.
83. Ulrik CS. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive
pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study.
Thorax 1995;50(7):750-4.
83
© 2006